Incyte Corporation is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing small‑molecule and biologic therapies, with core expertise in JAK inhibition and targeted oncology. Founded in 1991 and headquartered in Wilmington, Delaware, the company’s research and development spans hematology/oncology, dermatology, and immunology, supported by global operations and collaborations.
Incyte’s marketed portfolio includes ruxolitinib (sold as Jakafi in the United States and as Jakavi by partner Novartis outside the U.S.) for certain myeloproliferative neoplasms, a topical ruxolitinib formulation (Opzelura) for select inflammatory skin conditions, pemigatinib (Pemazyre) for FGFR2‑altered cholangiocarcinoma, and retifanlimab (Zynyz) for Merkel cell carcinoma. Incyte also discovered baricitinib, which is licensed to Eli Lilly. The company maintains a broad pipeline of targeted small molecules and antibodies and collaborates with partners including Novartis, Eli Lilly, and MorphoSys.
None yet. When a new project in the record names Incyte as owner, partner or investor, it shows here.
Phase 1/2 trial will combine an EGFR/LGR5 bispecific antibody with a KRAS G12D inhibitor plus chemotherapy as first‑line treatment for KRAS G12D‑mutant metastatic colorectal cancer.
Oral baricitinib showed substantial scalp, eyebrow and eyelash regrowth in a Phase 3 pediatric trial; 4 mg and 2 mg doses outperformed placebo at Week 36.
CHMP backs Olumiant for severe alopecia areata in adolescents, based on Phase 3 study showing 42% achieved 80% scalp hair coverage at 36 weeks. Awaiting European Commission decision.
